The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism

International Journal of Neuropsychopharmacology

Volumn 17, Issue 3, 2014, Pages 455-468

  Gonzalez Aparicio, Ramiro ^a,b   Blanco, Eduardo ^c,d   Serrano, Antonia ^c,e   Pavon, Francisco Javier ^c,e   Parsons, Loren H ^e   Maldonado, Rafael ^f   Robledo, Patricia ^f   Fernandez Espejo, Emilio ^a   De Fonseca, Fernando Rodriguez ^c  

^a INSTITUTO CAJAL   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d UNIVERSITY OF MÁLAGA   (Spain)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

6 hydroxydopamine; Dopaminergic neurons; Neuroprotection; Parkinson's disease; PPAR

Indexed keywords

HEME OXYGENASE 1; N OLEOYLETHANOLAMINE; OXIDOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEME OXYGENASE-1; L-LACTATE DEHYDROGENASE; MALE; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OLEIC ACIDS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYNAPTOPHYSIN; TYROSINE 3-MONOOXYGENASE;

EID: 84897852790     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001259     Document Type: Article

References (76)

1. Aguirre JA, Cintra A, Hillion J, Narvaez JA, Jansson A, Antonelli T, Ferraro L, Rambert FA, Fuxe K (1999) A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci Lett 275:215-218.
2. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 273:5678-5684.
3. Applegate LA, Luscher P, Tyrrell RM (1991) Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 51:974-978.
4. Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A (2002) The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 53:463-475.
5. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441-1444.
6. Berdyshev EV, Schmid PC, Dong Z, Schmid HH (2000) Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem J 346(Pt 2):369-374.
7. Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem Int 52:307-313.
8. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346.
9. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
10. Burke RE, Antonelli M, Sulzer D (1998) Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 71:517-525.
11. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OH-DA) in rats: behavioural and biochemical evidence. Brain Res 476:10-15.
12. Calabrese EJ, Baldwin LA (2001) U-shaped dose-responses in biology, toxicology, and public health. Annu Rev Public Health 22:15-33.
13. Cardozo DL (1993) Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience 56:409-421.
14. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OH-DA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998.
15. Cohen G, Heikkila RE, Allis B, Cabbat F, Dembiec D, MacNamee D, Mytilineou C, Winston B (1976) Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. J Pharmacol Exp Ther 199:336-352.
16. Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system. J Neurochem 70:1366-1375.
17. Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muia C, Crisafulli C, Caputi AP (2006) The role of the peroxisome proliferator-activated receptor-α (PPAR-α) in the regulation of acute inflammation. J Leukoc Biol 79:999-1010.
18. Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferatoractivated receptors in inflammation control. J Endocrinol 169:453-459.
19. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271.
20. Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK (2004) Ligands for the peroxisome proliferatoractivated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 148:116-126.
21. Ding YM, Jaumotte JD, Signore AP, Zigmond MJ (2004) Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 89:776-787.
22. El-Banoua F, Caraballo I, Flores JA, Galan-Rodriguez B, Fernandez-Espejo E (2004) Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model. Neurobiol Dis 16:377-385.
23. Fernandez-Espejo E (2004) Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 29:15-30.
24. Fernandez-Espejo E, Montoro RJ, Armengol JA, Lopez-Barneo J (1998) Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 20:197-206.
25. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425:90-93.
26. Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E (2009) Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacol 56:653-664.
27. Giuffrida A, Rodríguez de Fonseca F, Piomelli D (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 280(1):87-93.
28. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
29. Gravetter FJ, Wallnau LB (2007) Statistics for the behavioural sciences. Belmont, CA: Thomson Wadsworth.
30. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorenson FB, Vesterby A, West MJ (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Apmis 96:857-881.
31. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:S72-S84.
32. Kainu T, Wikstrom AC, Gustafsson JA, Pelto-Huikko M (1994) Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport 5:2481-2485.
33. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20:4686-4700.
34. Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T (2009) PPAR{α} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 296:F328-F336.
35. Kreisler A, Gele P, Wiart JF, Lhermitte M, Destee A, Bordet R (2007) Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 1135:77-84.
36. Lagares A, Avendaño C (1999) An efficient method to estimate cell number and volume in multiple dorsal root ganglia. Acta stereologica 18:185-195.
37. Lleo A, Galea E, Sastre M (2007) Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64:1403-1418.
38. Lombardi G, Miglio G, Varsaldi F, Minassi A, Appendino G (2007) Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine. J Pharmacol Exp Ther 320:599-606.
39. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-19.
40. Marqueze-Pouey B, Wisden W, Malosio ML, Betz H (1991) Differential expression of synaptophysin and synaptoporin mRNAs in the postnatal rat central nervous system. J Neurosci 11:3388-3397.
41. Mena MA, Davila V, Sulzer D (1997) Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 69:1398-1408.
42. Meuth S, Pape HC, Budde T (2002) Modulation of Ca2+currents in rat thalamocortical relay neurons by activity and phosphorylation. Eur J Neurosci 15:1603-1614.
43. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T (2000) Increase in level of tumor necrosis factor-α in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett 289:165-168.
44. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM (2005) Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci 28:189-194.
45. Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123:131-145.
46. Munoz AM, Rey P, Parga J, Guerra MJ, Labandeira-Garcia JL (2005) Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage. J Chem Neuroanat 29:113-126.
47. Na SJ, DiLella AG, Lis EV, Jones K, Levine DM, Stone DJ, Hess JF (2010) Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease. Neurochem Res 35:761-772.
48. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11:999-1016.
49. Okada M, Urae A, Mine K, Shoyama Y, Iwasaki K, Fujiwara M (1992) The facilitating and suppressing effects of delta 9-tetrahydrocannabinol on the rise in intrasynaptosomal Ca2+ concentration in rats. Neurosci Lett 140:55-58.
50. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3:167-175.
51. Pavon J, Serrano A, Romero-Cuevas M, Alonso M, Rodriguez de Fonseca F (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7:175-183.
52. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Burlington, MA: Academic Press.
53. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 272:27307-27312.
54. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
55. Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, Rodriguez de Fonseca F, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64: 379-389.
56. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647.
57. Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE (2006) Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr 136:700-703.
58. Rey P, Lopez-Real A, Sanchez-Iglesias S, Munoz A, Soto-Otero R, Labandeira-Garcia JL (2007) Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 28:555-567.
59. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D (2001) An anorexic lipid mediator regulated by feeding. Nature 414:209-212.
60. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415.
61. Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D (2002) Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33:2112-2114.
62. Schmidt A, Vogel R, Holloway MK, Rutledge SJ, Friedman O, Yang Z, Rodan GA, Friedman E (1999) Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family. Mol Cell Endocrinol 155:51-60.
63. Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331.
64. Smeyne M, Smeyne RJ (2002) Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease. Brain Res Brain Res Protoc 9:105-111.
65. Sterio DC (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134:127-136.
66. Su H-F, Samsamshariat A, Fu J, Shan YX, Chen Y-H, Piomelli D, Wang PH (2006) Oleylethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure. Endocrinology 147:827-834.
67. Suardiaz M, Estivill-Torrus G, Goicoechea C, Bilbao A, Rodriguez de Fonseca F (2007) Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133:99-110.
68. Sulcova E, Mechoulam R, Fride E (1998) Biphasic effects of anandamide. Pharmacol Biochem Behav 59:347-352.
69. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ (2007) Cannabinoid activation of PPAR α; a novel neuroprotective mechanism. Br J Pharmacol 152:734-743.
70. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
71. Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, Destaillats F (2008) Biological functions and metabolism of oleoylethanolamide. Lipids 43:887-894.
72. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-110.
73. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.
74. Walter L, Franklin A, Witting A, Moller T, Stella N (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277:20869-20876.
75. Wang X, Miyares RL, Ahern GP (2005) Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 564:541-547.
76. Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W, Chen C, Jin X (2012) Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor α. Neuropharmacology 63: 242-249.